Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  Data backs broader use of Pfizer’s Sutent in kidney cancer

Data backs broader use of Pfizer’s Sutent in kidney cancer

by | Jul 12, 2016 | Kidney Cancer News

A Phase III study pitting adjuvant use of Pfizer’s Sutent against a placebo in patients with kidney cancer

has met its primary endpoint of showing improved disease-free survival (DFS) in those taking the drug.
The S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer) is the first to test a tyrosine kinase inhibitor (TKI) to prolong DFS in the adjuvant setting, with the aim of lowering the risk of cancer recurrence in patients with early-stage disease.
Full data are yet to be revealed, but Mace Rothenberg, chief development officer of Oncology at Pfizer Global Product Development, said the firm believes the results “support the potential for Sutent to be a treatment option in a broader range of patients”.
The drugs giant also said it would be discussing the data with health authorities to determine an appropriate regulatory path forward for the drug in this setting.
Read the full article on PharmaTimes website here

<a href="" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.